Next-Gen MRD: Increasing Access to Ultrasensitive ctDNA Assessment for Biomarker Discovery, Development, & CDx Programs
Time: 11:50 am
day: Day 2 - Track A (1)
Details:
- The Pathlight MRD test is an ultrasensitive, cost-effective approach to MRD detection and quantification to <1 PPM using WGS proprietary dPCR methods to track structural variants
- Structural Variants (SVs) are highly prevalent across indications and are an ideal pan-cancer biomarker for determining MRD status
- Clinical studies in breast and ovarian cancers demonstrate improved detection of ctDNA at baseline, during neoadjuvant treatment, post-surgery, and during follow-up, with long lead times to clinical relapse
